Valeant Pharmaceuticals Announces Preliminary Results From Its Phase IIa Retigabine Study For The Treatment Of Postherpetic Neuralgia (PHN)
Valeant Pharmaceuticals International (NYSE: VRX) announced preliminary results from its Phase IIa proof-of-concept clinical trial of retigabine for the treatment of pain associated with postherpetic neuralgia (PHN), a painful and common complication of shingles. While retigabine was generally well tolerated, the study did not meet its pre-specified primary efficacy endpoint. Further detailed analyses are warranted and are ongoing.
Related Posts
Tags: neuralgia, pharmaceuticals, phase, postherpetic, preliminary, results, retigabine, study, treatment, valeant
This entry was posted on Thursday, August 27th, 2009 at 7:08 pm and is filed under Analgesics Pain Migraine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
